Dr. Robert Ryan, Chief Executive Officer of Nuvilex, added, “We are hopeful that through use of our cell encapsulation platform patients will no longer have to rely on daily insulin injections. The ultimate objective, if future trials prove effective, will be for patients to receive encapsulated live cell treatments intermittently, possibly as infrequently as every 3 to 6 months or longer, dramatically changing their lives.”Investors are recommended to study the Goldman Research Report for a detailed review and valuation methodology regarding Nuvilex. About Nuvilex Nuvilex, Inc. (OTCQB: NVLX) is an emerging international biotechnology provider of biotechnology and clinically useful, therapeutic live-cell encapsulation products and services for the research and medical communities. Through substantial effort, Nuvilex and SG Austria are rapidly moving toward our initial phase of funding acquisition and initial agreement completion. One of our first planned offerings is to include cancer treatments using the company’s industry-leading live-cell encapsulation technology. Safe Harbor Statement The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Nuvilex’s ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
Nuvilex, Inc. (OTCQB: NVLX), an emerging biotechnology provider of cell and gene therapy solutions, today provided additional details based on the Goldman Small Cap Research report issued February 29, 2012, that highlighted the company’s cell encapsulation technology and its benefits for treating chronic diseases such as diabetes. The Company’s technology involves encapsulating insulin-producing cells that respond to changes in glucose levels into the Cell-in-a-Box® platform. As a result, the treatment would potentially eliminate the need for diabetes patients to continually test their glucose levels and inject insulin. The Goldman report cited the completed animal study wherein SG Austria successfully treated diabetes in an established, recognized animal model utilizing live encapsulated cells. In the study, the introduced cells responded to elevated blood sugar levels by producing insulin, thereby alleviating the symptoms of diabetes. Moreover, encapsulated cells remained viable and responsive for many months. The report stated, “This data, as well as previously published results, demonstrate it is feasible to overcome the basis for diabetes by implanting encapsulated, insulin-producing cells. This should pave the way for future clinical trials of encapsulated cells as a means to continuously regulate blood glucose for months, eliminating the need for daily glucose assessment and insulin injections. Such treatment would present a more natural means of providing insulin to patients, mimicking the body's own insulin production and thereby maintaining healthy blood glucose levels. “The long term effects of diabetes include kidney failure, blindness, heart disease, amputations, and stroke. The World Health Organization (WHO) reports 346 million people in the world have diabetes and 4 million deaths occur globally each year. In fact, more than $378 billion is spent annually on diabetes treatment with the number expected to rise to $490 billion by 2030.” The report concluded that, “Although it is early in the development process, the prospects on the diabetes front could be huge for the Company.” Goldman set a current value of Nuvilex at $0.30 per share with a six month price target of $0.50 per share based on the cell encapsulation technology and the favorable clinical and pre-clinical trial results across multiple biotechnology fields.